Calibr at Scripps Research
Mary Sullivan, Ph.D. has a strong background in corporate development and innovation. Mary currently holds the role of VP of Corporate Development at Calibr at Scripps Research and Sr. Director of Corporate Development at Scripps Research. Prior to these positions, they worked at UCLA Technology Development Group as a Senior Principal and Principal of UCLA Innovation Fund & New Ventures. Mary also has experience as a Senior Life Sciences Specialist at L.E.K. Consulting and as a Blavatnik Associate at Yale Office of Cooperative Research. Mary has a Ph.D. in biomedical sciences from Yale University School of Medicine and has been involved in various entrepreneurial and educational roles at Yale University and Yale School of Management.
Mary Sullivan, Ph.D. holds a Doctor of Philosophy (PhD) degree in Neuroscience from Yale University. Mary completed their undergraduate studies at Oberlin College, where they earned a Bachelor of Arts (BA) degree in Neuroscience and French. In addition, they have pursued studies in French Literature, French Language, Art History, and French History and Culture at Université Inter-Ages du Dauphiné. Prior to their higher education, they received their high school diploma from Phillips Exeter Academy.
This person is not in any offices
Calibr at Scripps Research
1 followers
The California Institute for Biomedical Research (Calibr) is a first-of-its-kind, nonprofit translational research institute dedicated to accelerating the next generation of medicines. Affiliated with Scripps Research—among the most innovative institutes worldwide—we spearhead drug discovery from a steady flow of pioneering science. Our self-sustaining model encourages broad and bold exploration with far-reaching goals, yet rapid transition of our most successful, high-impact programs into the clinic. We pursue audacious and imaginative ideas—bridging scientific and technological advances to develop new medicines for unmet medical needs. Our pipeline programs range from cancer to infectious diseases and from discovery to early clinical trial stages, all aimed at preventing disease and healing humans around the world. We bring together leaders in research, drug development, and business to answer important biological questions and develop new interventions to treat, cure, and prevent disease. Our infrastructure and expertise extend from high-throughput screening and protein engineering to pharmacology and clinical development. Calibr’s research space includes a newly renovated 35,000 square foot facility in La Jolla, CA, which houses over 100 interdisciplinary scientists and staff with state-of-the-art instrumentation. This infrastructure, combined with Calibr’s drug discovery expertise, enables projects rooted in novel therapeutic mechanisms to progress from the laboratory through preclinical development and ultimately to the clinic through commercial, federal, or foundation partnerships.